French study shows benefits of Biofield's BBE
This article was originally published in Clinica
Results of a French study using Biofield's (US) BBE breast cancer detection device show it can outperform conventional mammography. Prof Lamarque (Montpellier) and Dr Vanel (Paris), who presented their results at the Journees Francaises de Radiologie '95 in Paris last week, showed the non-invasive device has a sensitivity of 92% and specificity of 59%. Some 119 BBE tests were carried out on 66 benign and 53 malignant lesions, giving a negative predictive value of 91% and positive predictive value of 65%. This compares favourably with mammography which is estimated to have a sensitivity of 85%-90% and a specificity of 20-40%.
You may also be interested in...
Butterfly Network chose SPAC route with Longview Acquisition Corp. to scale its business and expand into the home market in 2021.
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says
As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.